

## Announcement

# Mar Cor Purification Announces it has Shipped it's 12,000<sup>th</sup> Portable RO for Dialysis Applications

*...12,000<sup>th</sup> unit was the popular Millenium™ sold to Fresenius Walnut Creek*

**Plymouth, MN**, (October 2009) Mar Cor Purification, Inc. announced that it has shipped the 12,000<sup>th</sup> portable RO used in single patient dialysis applications. The unit was sold to Fresenius Medical Care (FMC) for use in treating patients in home and acute settings. The total includes RO systems marketed under the following product names; Millenium™, Semper Pure™, F-801, and the 700 Series. These machines produce high purity water to feed artificial kidney machines that help end stage renal disease (ESRD) patients live better lives. With the increasing number of dialysis patients and the trend towards home dialysis, Mar Cor's products are chosen for their reliability and ease of operation.

According to Mike Verguldi, Medical Product Manager at Mar Cor Purification, "This really is a strong endorsement to Mar Cor's commitment to building quality equipment that meets the high regulatory compliance necessary to conduct business in this medical arena. We are honored by our customers' trust as they rely on our equipment for safe treatment of their patients."

Along with the portable RO products, Mar Cor Purification offers complete water treatment equipment, filtration and disinfection technologies. The filtration products include unique FiberFlo® hollow fiber membrane filters designed to protect products and processes from bacterial and endotoxin contamination. Minncare® Cold Sterilant is ideal for water and process system sanitization and is also used with our proprietary Minncare Dry Fog® and Mini-Fog™ Systems. Actril® Cold Sterilant is a sporicidal surface disinfectant that is used in critical surface disinfection applications. For information on any of our products and services, please call 1-800-633-3080 to speak to a Customer Service representative.

Mar Cor Purification, a wholly owned subsidiary of Cantel Medical Corp. (NYSE:CMN), has service offices in 18 cities in the US and Canada with six ion exchange resin regeneration plants strategically located in Atlanta, Boston, Chicago, Philadelphia, Montreal and Toronto. Mar Cor Purification has representatives located at more than 30 sites throughout the world to provide sales and technical support. We offer support with design engineering capabilities, 24/7 service coverage, field application sales, experienced service technicians, and a fleet of stocked service vehicles. Mar Cor Purification is dedicated to providing innovative solutions through filtration, water, and disinfection technologies. Visit our website at <http://www.mcpur.com>.

Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens. For further information, visit the Cantel website at <http://www.cantelmedical.com>.

*Actril® Cold Sterilant is a registered trademark of Minntech Corporation and is an US-EPA registered product (52252-7). Minncare® Cold Sterilant is a registered trademark of Minntech Corporation and is an US-EPA registered product (52252-4). FiberFlo® is a registered trademark of Minntech Corporation. Minncare Dry Fog® is a registered trademark of Minntech Corporation and Mini-Fog™ System is a trademark of Minntech Corporation.*

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.*

SOURCE: Mar Cor Purification

Contact information:

Christopher Fournier  
cfournier@mcpur.com  
Vice President Marketing  
Mar Cor Purification  
Phone: 978-453-9600